Hologic, Inc. ("Hologic" or the "Company") seeks to amend its senior secured credit facilities (the "Credit Facility Repricing"). A meeting is scheduled between senior officers of the Company and prospective lenders to be held on March 5, 2013 related to the Credit Facility Repricing. The terms of the Credit Facility Repricing are expected to include a reduction in the interest rates on the Company's existing $1.0 billion senior secured tranche A term loan with a final maturity date of August 1, 2017 and the Company's existing $300.0 million secured revolving credit facility with a final maturity date of August 1, 2017, and certain other amendments. The repricing is subject to market and other conditions, including obtaining the requisite consent of the lenders. The Company cannot assure that such Credit Facility Repricing will be completed on the terms contemplated, or on a timely basis, if at all.

Attached hereto as Exhibit 99.1 are certain slides from an investor presentation that the Company plans to present to its lenders for the Credit Facility Repricing.

Limitation on Incorporation by Reference. The information furnished in this Item 7.01, including the investor presentation attached hereto as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the investor presentation attached as an exhibit hereto, the investor presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes above and in the investor presentation regarding these forward-looking statements.

(d) Exhibits.

                         Exhibit
                         Number    Description

                         99.1      Investor presentation.